Fennec Drug Patent Portfolio
Fennec owns 1 orange book drug protected by 7 US patents Given below is the list of Fennec's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11291728 | Anhydrous sodium thiosulfate and formulations thereof | 01 Jul, 2039 | Active |
| US11510984 | Anhydrous sodium thiosulfate and formulations thereof | 01 Jul, 2039 | Active |
| US11617793 | Anhydrous sodium thiosulfate and formulations thereof | 01 Jul, 2039 | Active |
| US11964018 | Therapeutic uses for sodium thiosulfate formulations | 01 Jul, 2039 | Active |
| US11992530 | Therapeutic uses for sodium thiosulfate and formulations | 01 Jul, 2039 | Active |
| US11998604 | Therapeutic uses for sodium thiosulfate formulations | 01 Jul, 2039 | Active |
| US10596190 | Method for reducing ototoxicity in pediatric patients receiving platinum-based chemotherapy | 05 Jan, 2038 | Active |
Latest Legal Activities on Fennec's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Fennec.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Yr, Small Entity | 17 Sep, 2025 | US11291728 |
| Email Notification | 27 Aug, 2024 | US11291728 |
| Mail Patent eCofC Notification | 27 Aug, 2024 | US11291728 |
| Patent eCofC Notification | 27 Aug, 2024 | US11291728 |
| Recordation of Patent eCertificate of Correction | 27 Aug, 2024 | US11291728 |
| Electronic Review | 31 Jul, 2024 | US11992530 |
| Email Notification | 30 Jul, 2024 | US11992530 |
| Patent eCofC Notification | 30 Jul, 2024 | US11992530 |
| Mail Patent eCofC Notification | 30 Jul, 2024 | US11992530 |
| Recordation of Patent eCertificate of Correction | 30 Jul, 2024 | US11992530 |
| Patent eCofC Notification | 16 Jul, 2024 | US11617793 |
|
Email Notification
Critical
| 16 Jul, 2024 | US11617793 |
| Recordation of Patent eCertificate of Correction | 16 Jul, 2024 | US11617793 |
| Mail Patent eCofC Notification | 16 Jul, 2024 | US11617793 |
| Electronic Review | 07 Jun, 2024 | US11992530 |
Fennec's Drug Patent Litigations
Fennec's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Oct 29, 2021, against patent number US10596190. The petitioner Hope Medical Enterprises, Inc., challenged the validity of this patent, with Oregon Health & Science University et al. as the respondent. Click below to track the latest information on how companies are challenging Fennec's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US10596190 | October, 2021 |
Final Written Decision
(18 Apr, 2023)
| Oregon Health & Science University et al. | Hope Medical Enterprises, Inc. |
Fennec's Family Patents
Fennec Drug List
Given below is the complete list of Fennec's drugs and the patents protecting them.
1. Pedmark
Pedmark is protected by 7 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11291728 | Anhydrous sodium thiosulfate and formulations thereof |
01 Jul, 2039
(13 years from now)
| Active |
| US11510984 | Anhydrous sodium thiosulfate and formulations thereof |
01 Jul, 2039
(13 years from now)
| Active |
| US11617793 | Anhydrous sodium thiosulfate and formulations thereof |
01 Jul, 2039
(13 years from now)
| Active |
| US11964018 | Therapeutic uses for sodium thiosulfate formulations |
01 Jul, 2039
(13 years from now)
| Active |
| US11992530 | Therapeutic uses for sodium thiosulfate and formulations |
01 Jul, 2039
(13 years from now)
| Active |
| US11998604 | Therapeutic uses for sodium thiosulfate formulations |
01 Jul, 2039
(13 years from now)
| Active |
| US10596190 | Method for reducing ototoxicity in pediatric patients receiving platinum-based chemotherapy |
05 Jan, 2038
(11 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Pedmark's drug page